肿瘤药学2025，Vol.15Issue(5)：640-646,7.DOI:10.3969/j.issn.2095-1264.2025.05.09
安维汀与安可达治疗非小细胞肺癌的研究进展
Research progress of Avastin and Ankeda in the treatment of non-small cell lung cancer
摘要
Abstract
Bevacizumab and its biosimilar,Ankeda(the first bevacizumab biosimilar approved in China),have demon-strated significant efficacy in the treatment of non-small cell lung cancer(NSCLC),providing crucial therapeutic options.This review focuses on a comparative analysis of Avastin(the originator bevacizumab)and Ankeda,both of which are repre-sentative agents in clinical practice and health policy.Their mechanism of action involves targeted inhibition of vascular en-dothelial growth factor(VEGF),thereby suppressing tumor angiogenesis and growth.Clinical evidence confirms that this mechanism translates into significant extensions of both progression-free survival and overall survival.Studies have estab-lished high similarity between Ankeda and Avastin in terms of efficacy,safety,and immunogenicity.Furthermore,the en-hanced cost-effectiveness of Ankeda significantly improves treatment accessibility.The combination of either agent with chemotherapy demonstrates a synergistic effect,improving the objective response rate and patient quality of life.Future ef-forts to optimize treatment regimens and develop novel therapeutic agents remain pivotal for advancing outcomes in NSCLC management.关键词
贝伐珠单抗/非小细胞肺癌/安维汀/安可达/临床疗效Key words
Bevacizumab/Non-small cell lung cancer/Avastin/Ankeda/Clinical efficacy分类
医药卫生引用本文复制引用
YU Chen,LÜ Xiaolin,LIU Anchang..安维汀与安可达治疗非小细胞肺癌的研究进展[J].肿瘤药学,2025,15(5):640-646,7.基金项目
山东省医学会临床科研资金——齐鲁专项(YXH2022ZX02053). （YXH2022ZX02053）
